Bellevue Life Sciences Acquisition Corp.
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Bellevue Life Sciences Acquisition Corp. generated cash of -$818,766, which is less than the previous year. Cash used in financing activities reached the amount of $34,539,499 last year. Net change in cash is therefore -$109,082.
Cash Flow
| 2022 | -4.23K | 0 | 123.97K |
|---|---|---|---|
| 2023 | -818.76K | -33.82M | 34.53M |
BLACU Cash Flow Statement (2022 – 2023)
| 2023 | 2022 | |
|---|---|---|
Cash at beginning of period | 124.50K | 4.75K |
Operating activities | ||
Net income | 403.78K | -35.38K |
| Adjustments to reconcile net income to cash generated by operating activities: | ||
Depreciation and amortization | 0 | 0 |
Stock-based compensation expense | 0 | 0 |
| Deferred income tax benefit | 0 | 0 |
| Changes in operating assets and liabilities: | ||
Accounts receivable, net | 0 | 0 |
Inventories | 0 | 0 |
Accounts payable | 1.03M | 31.15K |
Cash generated by operating activities | -818.76K | -4.23K |
Investing activities | ||
Purchases Of Investments | 0 | 0 |
Investments In Property Plant And Equipment | 0 | 0 |
Acquisitions Net | 0 | 0 |
Cash generated by investing activities | -33.82M | 0 |
Financing activities | ||
Common Stock Issued | 63.97M | -683.02K |
Payments for dividends | 0 | 0 |
Repurchases of common stock | -35.99M | 0 |
Repayments of term debt | -1.2M | 800K |
Cash used in financing activities | 34.53M | 123.97K |
Net Change In Cash | -109.08K | 119.74K |
Cash at end of period | 15.41K | 124.50K |
| Data source | Data source |